Evidence map›Paper›PMID 23704171›Full record

ArticleBMJ (Clinical research ed.)2013

Risk of incident diabetes among patients treated with statins: population based study.

Aleesa A Carter, Tara Gomes, Ximena Camacho, David N Juurlink, Baiju R Shah, Muhammad M Mamdani

Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ (Clinical research ed.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 163 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 10 pooled it
56.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06676683 not yet recruitingstarted 2024, after this paper: background citation

The Use of Statin in Diabetic Patients Not Known to Have Atherosclerotic Cardiovascular Disease in a Low Income Community

Ran2024Enrolled300Registered outcomes1Posted comparisons0ConditionsDiabete Type 2ArmsUsage of Statin in diabetic patients
PMID 28437620PMID 27829091PMID 30851939PMID 30642643PMID 23186103PMID 23440795PMID 34135017PMID 18367002PMID 18691566PMID 30879355PMID 31504418other papers from this trial
Open the trial in the graph
NCT06767774 phase4recruitingstarted 2025, after this paper: background citation

Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With Atherosclerotic Cardiovascular Disease

Ran2025Enrolled2,000Registered outcomes13Posted comparisons0ConditionsASCVD, Diabetes, StatinArmsCombination therapy, High intensity statin monotherapy
PMID 29263150PMID 21693744PMID 20167359PMID 12186811PMID 30586774PMID 10333939PMID 11270938PMID 17601626PMID 17559928PMID 12087009PMID 30586775PMID 31466435other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 10 syntheses or guidelines pooled it, 409 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial.The Journal of clinical endocrinology and metabolism · 2018
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Trial
  19. Trial
  20. Trial

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Aleesa A CarterToronto General Hospital, Toronto, ON, Canada M5G 2C4.
Tara Gomes
Ximena Camacho
David N Juurlink
Baiju R Shah
Muhammad M Mamdani
Institute for Clinical Evaluative Sciences · CASt. Michael's Hospital · CASunnybrook Health Science Centre · CAToronto General Hospital · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).

designPopulation based cohort study with time to event analyses to estimate the relation between use of particular statins and incident diabetes. Hazard ratios were calculated to determine the effect of dose and type of statin on the risk of incident diabetes.

settingOntario, Canada.

participantsAll patients aged 66 or older without diabetes who started treatment with statins from 1 August 1997 to 31 March 2010. The analysis was restricted to new users who had not been prescribed a statin in at least the preceding year. Patients with established diabetes before the start of treatment were excluded.

interventionsTreatment with statins.

main outcome measureIncident diabetes.

resultsCompared with pravastatin (the reference drug in all analyses), there was an increased risk of incident diabetes with atorvastatin (adjusted hazard ratio 1.22, 95% confidence interval 1.15 to 1.29), rosuvastatin (1.18, 1.10 to 1.26), and simvastatin (1.10, 1.04 to 1.17). There was no significantly increased risk among people who received fluvastatin (0.95, 0.81 to 1.11) or lovastatin (0.99, 0.86 to 1.14). The absolute risk for incident diabetes was about 31 and 34 events per 1000 person years for atorvastatin and rosuvastatin, respectively. There was a slightly higher [corrected] absolute risk with simvastatin (26 outcomes per 1000 person years) compared with pravastatin (23 outcomes per 1000 person years). Our findings were consistent regardless of whether statins were used for primary or secondary prevention of cardiovascular disease. Although similar results were observed when statins were grouped by potency, the risk of incident diabetes associated with use of rosuvastatin became non-significant (adjusted hazard ratio 1.01, 0.94 to 1.09) when dose was taken into account.

conclusionsCompared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.

Indexed as

AgedAtorvastatinCardiovascular DiseasesCohort StudiesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDyslipidemiasFemaleFluorobenzenesHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleOdds RatioOntarioAtorvastatinFluorobenzenesHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinPyrimidinesPyrrolesRosuvastatin CalciumSimvastatinSulfonamides

Identifiers

PMID23704171
PMCPMC3662830
OpenAlexW1999320125

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.